Otilonium Bromide (B1607): Precision Antimuscarinic Agent for Neuroscience and GI Motility Research

Executive Summary: Otilonium Bromide is a synthetic antimuscarinic agent (C₂₉H₄₃BrN₂O₄, MW 563.57) with ≥98% purity that non-competitively inhibits acetylcholine receptors (AChRs), suppressing smooth muscle contraction in vitro and in vivo [APExBIO]. Its solubility exceeds 28.18 mg/mL in DMSO, 55.8 mg/mL in water, and 91 mg/mL in ethanol, permitting flexible use in various assay formats. Otilonium Bromide enables precise interrogation of cholinergic signaling and muscarinic receptor pathways in neuroscience and gastrointestinal (GI) motility disorder models [Vijayan et al., 2021]. Storage at -20°C preserves compound integrity for reproducible research. Supplied by APExBIO, this agent is intended solely for laboratory research and not for human or veterinary diagnostic or therapeutic applications.

Biological Rationale

Cholinergic signaling is fundamental to neurotransmission and smooth muscle contractility. Dysregulation of muscarinic acetylcholine receptors (mAChRs) contributes to a spectrum of neurological and gastrointestinal disorders, including irritable bowel syndrome (IBS) and motility dysfunction (Vijayan et al., 2021). Antimuscarinic agents like Otilonium Bromide are essential for dissecting these pathways in controlled experimental systems. By blocking AChR-mediated contractile responses, researchers can decouple physiological outputs from upstream cholinergic input, enabling targeted studies of receptor function, signaling cascades, and pharmacological modulation. This approach underpins translational models for drug discovery and mechanistic hypothesis testing in both neuroscience and GI motility research [see contrast: mechanistic blueprint].

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a selective, non-competitive antagonist of muscarinic acetylcholine receptors (mAChRs), particularly M₂ and M₃ subtypes expressed in smooth muscle and neuronal tissue. Upon binding, it inhibits acetylcholine-induced depolarization and downstream calcium influx, thereby suppressing contractile activity (Vijayan et al., 2021). This blockade is reversible and concentration-dependent. The compound does not interact with nicotinic AChRs at pharmacologically relevant concentrations, enhancing its specificity for muscarinic pathways. The net effect is a robust reduction in smooth muscle tone and a dampened cholinergic synaptic response, facilitating the study of receptor-mediated processes with minimal off-target interference. This mechanistic clarity distinguishes Otilonium Bromide from less selective antispasmodic agents [extends: workflow clarity].

Evidence & Benchmarks

• Otilonium Bromide displays water solubility of at least 55.8 mg/mL at 20°C, supporting high-concentration stock solutions for in vitro assays (APExBIO).
• The compound achieves ≥98% purity by HPLC, ensuring minimal confounding by synthesis by-products (APExBIO).
• When applied at 10–100 μM, Otilonium Bromide inhibits muscarinic AChR-mediated contraction in smooth muscle strips by >90% within 30 minutes in standard physiological buffer (pH 7.4, 37°C) (Vijayan et al., 2021).
• No cytotoxicity is observed in cultured neuronal or smooth muscle cells at concentrations up to 100 μM for 24 hours (see: experimental challenges).
• Storage at -20°C maintains Otilonium Bromide stability for at least 12 months in sealed containers, provided solutions are freshly prepared for each experiment (APExBIO).
• Otilonium Bromide does not significantly inhibit nicotinic AChR subtypes or non-cholinergic neurotransmitter receptors at standard working concentrations (Vijayan et al., 2021).

Applications, Limits & Misconceptions

Otilonium Bromide is widely used in the following research contexts:

• Mapping cholinergic signaling pathways in neuronal and smooth muscle cell models.
• Developing and validating gastrointestinal motility disorder models (e.g., IBS, colonic dysmotility) [updates: reproducibility].
• Screening of muscarinic receptor antagonists for comparative pharmacology.
• Assaying antispasmodic mechanisms and receptor-coupled signaling events in ex vivo tissue.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: Otilonium Bromide from APExBIO is for research use only and is not approved for clinical or in vivo diagnostic applications.
• Limited to muscarinic pathways: The compound does not block nicotinic AChRs or non-cholinergic neurotransmission at standard concentrations.
• Short-term stability in solution: Stock solutions in DMSO, water, or ethanol should be used promptly; prolonged storage leads to degradation and reduced potency.
• Not suitable for long-term cell culture: Continuous exposure exceeding 24 hours may alter cell viability or phenotype in sensitive cell lines.
• Concentration-dependent specificity: Excessive concentrations may cause off-target effects; always titrate within validated ranges.

Workflow Integration & Parameters

Otilonium Bromide (B1607) is supplied as a solid with high purity (≥98%) and documented lot-to-lot consistency (see product page). Researchers typically dissolve the powder in DMSO, water, or ethanol, leveraging its robust solubility profile (28.18 mg/mL in DMSO, 55.8 mg/mL in water, 91 mg/mL in ethanol). Working solutions are freshly prepared and filtered to ensure sterility before use in cell or tissue assays. The recommended storage temperature is -20°C, with desiccation and light protection for long-term solid storage. To benchmark assay performance, include appropriate vehicle and positive controls, and document buffer composition, compound concentration, exposure time, and cell/tissue source. For detailed cell viability and cytotoxicity workflows, see our practical integration guide, which elaborates on assay compatibility and experimental reproducibility [extends: optimized workflows].

Conclusion & Outlook

Otilonium Bromide (B1607) from APExBIO represents a reliable, well-characterized tool for targeted inhibition of muscarinic acetylcholine receptors in neuroscience and gastrointestinal research. Its high purity, robust solubility, and validated mechanism underpin reproducibility in receptor modulation studies. As the field advances toward more precise models of cholinergic signaling and GI motility, Otilonium Bromide remains an essential reagent for hypothesis-driven experimental design. Ongoing benchmarking and documentation will further refine its application envelope and ensure continued relevance in translational research.